Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspen Pharmacare HoldingsJSE:APN +0.70%72 5-Year Yield-on-Cost % is 1.43 as of Aug. 02, 2026, which is 21% below its 10-year median of 1.80. GuruFocus rates JSE:APN with a GF Score™ of 72/100 and a GF Value™ of R167.48 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 513 Drug Manufacturers companies, Aspen Pharmacare Holdings ranks worse than 64.33% on this metric.
The historical rank and industry rank for Aspen Pharmacare Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:
JSE:APN'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.57 Med: 1.8 Max: 4.54
Current: 1.43
During the past 13 years, Aspen Pharmacare Holdings's highest Yield on Cost was 4.54. The lowest was 0.57. And the median was 1.80.
JSE:APN's 5-Year Yield-on-Cost % is ranked worse than 64.33% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs JSE:APN: 1.43
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Aspen Pharmacare Holdings 5-Year Yield-on-Cost % Related Terms
JSE:APN vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspen Pharmacare Holdings 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Aspen Pharmacare Holdings's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Aspen Pharmacare Holdings (JSE:APN) has a 5-Year Yield-on-Cost % of 1.43 as of Aug. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Aspen Pharmacare Holdings and its competitors. This is 21% below median its historical median of 1.80. Over the past decade, Aspen Pharmacare Holdings' 5-Year Yield-on-Cost % has ranged from 0.57 to 4.54. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #330 out of 513 companies in the Drug Manufacturers industry, placing it in the top 64.3%.
Is Aspen Pharmacare Holdings' 5-Year Yield-on-Cost % too high?
Aspen Pharmacare Holdings' current 5-Year Yield-on-Cost % of 1.43 is 21% below median its 10-year median of 1.80. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 4.54. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.32. Aspen Pharmacare Holdings' value of 1.43 is 38.4% below this industry median. Based on the distribution chart, Aspen Pharmacare Holdings ranks #330 out of 513 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aspen Pharmacare Holdings has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #330 out of 513 companies for 5-Year Yield-on-Cost %. This places Aspen Pharmacare Holdings in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.32. Aspen Pharmacare Holdings' value of 1.43 is 38.4% below this benchmark. Historically, Aspen Pharmacare Holdings' own 5-Year Yield-on-Cost % has ranged from 0.57 to 4.54 over the past decade. While the company's 10-year median is 1.80 vs. the industry median of 2.32, Aspen Pharmacare Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.32, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspen Pharmacare Holdings's current 5-Year Yield-on-Cost % of 1.43 is 38.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Aspen Pharmacare Holdings and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspen Pharmacare Holdings's current 5-Year Yield-on-Cost % is 1.43, which is 21% below median its own 10-year median of 1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (JSE:APN) is currently considered Modestly Undervalued. The stock's GF Value™ is R167.48, compared to a current price of R149.10 — trading 11% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.43, which is 21% below median its 10-year median of 1.80 and 38.4% below the Drug Manufacturers industry median of 2.32. Aspen Pharmacare Holdings' overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Aspen Pharmacare Holdings (JSE:APN), the current 5-Year Yield-on-Cost % is 1.43 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspen Pharmacare Holdings (JSE:APN) Overvalued in 2026?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued.
The current stock price of R149.10 is trading 11% below its estimated GF Value™ of R167.48.
GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.
Key valuation signals for JSE:APN:
5-Year Yield-on-Cost %: 1.43 (21% below median its 10-year median of 1.80)
GF Value™: R167.48 vs. price of R149.10 (11% below fair value)
Industry Position: 38.4% below the Drug Manufacturers median (#330 of 513)
No single metric tells the full story. See the JSE:APN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
72GF Score
Get the complete analysis for JSE:APN
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:APN has been successfully added to your 
